Life Sciences

FIH Partners advised Novo A/S on the agreement to acquire a significant minority stake in Synlab

Learn more

Life Sciences

FIH Partners advised Novo A/S on the acquisition of Sonion

Learn more

Life Sciences

FIH Partners advised Ambu in the acquisition of King Systems, US

Learn more

Life Sciences

Since the dawn of biotech IPOs in Denmark in the mid-1990s, the partners of FIH Partners have been actively advising pharma, medtech, biotech and medical supplies companies.

Over the years, we have developed a detailed understanding of the commercial, scientific and regulatory drivers and risks associated with operating in the sector.

Examples of our experience in healthcare:

  • Advisor to Novo A/S in the agreement with Cinven and Ontario Teachers’ Pension Plan to acquire a substantial minority equity stake in Synlab
  • Advisor to Novo A/S in the acquisition of Sonion, a global leader in micro-acoustic technologies used for hearing instruments, for in-ear earphones and in specialty headsets, from Altor Fund III
  • Advisor to Ambu, listed on the OMX Nordic exchange, in the acquisition of King Systems, a US subsidiary of UK-listed Consort Medical
  • Advisor to Glycom in the acquisition of Vitalys’ manufacturing facility in Denmark
  • Advisor to ALK-Abelló in several acquisitions, including the acquisition of Artu Biologicals from Dutch-listed company Fornix BioSciences
  • Advisor to Altor Equity Partners in the acquisition of Pulse Medtech from US-based Technitrol
  • The partners of FIH Partners advised AP Møller Maersk on the divestment of Maersk Medical (Unomedical) to Nordic Capital
  • The partners advised the majority shareholder and board of Radiometer in the divestment of the company to US-based Danaher Corporation
  • Also, the partners advised on the IPOs of Bavarian Nordic, Genmab, NeuroSearch and Pharmexa